Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capivasertib - AstraZeneca

Drug Profile

Capivasertib - AstraZeneca

Alternative Names: AZD 5363; Truqap

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
  • Developer AstraZeneca
  • Class Antineoplastics; Piperidines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered HER2 negative breast cancer
  • Phase III Prostate cancer; Triple negative breast cancer
  • Phase II Breast cancer; Endometrial cancer; Gastric cancer; Meningioma; Non-Hodgkin's lymphoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Preclinical Diffuse large B cell lymphoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 29 Apr 2024 CHMP recommends approval of Capivasertib for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in European Union
  • 27 Mar 2024 Registered for HER2-negative-breast-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in Japan (PO)
  • 05 Dec 2023 Efficacy and adverse events data from a phase Ib/III CAPItello-292 trial in breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top